Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy.

Dario CattaneoLuca PasinaAldo Pietro MaggioniAndrea GiacomelliLetizia OreniAlice CovizziLucia BradaniniMarco SchiumaSpinello AntinoriAnnalisa RidolfoCristina Gervasoni

Published in: Drugs & aging (2020)

Among hospitalised patients with COVID-19, concomitant treatment with lopinavir/ritonavir and hydroxychloroquine led to a dramatic increase in the number of potentially severe DDIs. Given the high risk of cardiotoxicity and the scant and conflicting data concerning their efficacy in treating SARS-CoV-2 infection, the use of lopinavir/ritonavir and hydroxychloroquine in patients with COVID-19 with polypharmacy needs to be carefully considered.

Keyphrases

adverse drug
antiretroviral therapy
healthcare
electronic health record
early onset
drug induced
big data
machine learning
coronavirus disease
deep learning